ROIC surged from -9.72% to 6.01% over seven years while market expectations imply only 6.09% growth.
DexCom's 6.09% market-implied growth exceeds its 4.2% actual growth, yet the expectations gap may be justified by the company's transformation from growth to profitability optimization.
What expectations are embedded in the price, and are they reasonable?
This framework sees the market pricing in growth acceleration from current 4.2% to 6.09% perpetual, which exceeds current performance but remains below historical 15.6% TTM rate. The 66.3% price decline suggests expectations have already reset significantly, creating a moderate positive gap.
Is the business creating or destroying value?
Applying this lens reveals DexCom still destroys value with ROIC below WACC, but the trajectory is exceptional - from massive destruction to near break-even. The framework recognizes this dramatic improvement trend matters more than the current negative spread.
How long can the company earn returns above its cost of capital?
This framework identifies strong evidence of a lengthening CAP - expanding margins, demonstrated pricing power, and long-term institutional commitment suggest sustainable advantages. The CGM device switching costs and healthcare necessity create durable moats.
Is growth creating or destroying value?
The framework sees a fundamental shift - slower revenue growth producing higher cash flows and margins suggests value-creating efficiency gains. Operating leverage of 7.99x means each revenue point generates 8 points of profit growth, transforming modest growth into substantial value creation.
Applying the Mauboussin framework reveals a classic expectations recalibration opportunity. The market prices 6.09% growth for a business delivering 4.2%, yet this modest premium seems reasonable given the dramatic profitability transformation and lengthening competitive advantage period. The framework suggests the 66.3% drawdown has already reset expectations to achievable levels. Is the market still fighting the last war of growth deceleration while missing the new war of margin expansion?
This analysis applies Michael Mauboussin's published investment framework to publicly available financial data. It is not authored by, endorsed by, or affiliated with Michael Mauboussin. Educational purposes only. Not financial advice.